Aridol®

Pharmaxis' first commercial product, Aridol is an innovative lung function test designed to help doctors diagnose and manage asthma by detecting active airway inflammation through measuring airway hyper-responsiveness. Patients inhale increasing doses of Aridol via a simple hand-held device. Respiratory clinicians administering the test measure the patient's lung function to identify airway inflammation which can assist doctors in providing appropriate asthma treatment. Aridol is approved for sale in Australia, major European countries and South Korea. It is the first and only approved Europe-wide approved bronchial challenge test and the world's first approved indirect challenge test for asthma, a condition which affects 52 million people worldwide. Aridol is used in investigator-sponsored clinical trials worldwide. It has also been included in both international and Australian official guidelines for managing asthma. Bodies and guidelines referencing Aridol include:

  • Global Initiative for Asthma (GINA) Report on Global Strategy for Asthma Management and Prevention
  • Australian Asthma Management Handbook
  • Australian Sports Drug Medical Advisory Committee (ASDMAC)

To visit the Aridol website click here